¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chronic active hepatitis, NEC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • hepatitis G virus
    GÇü°£¿°¹ÙÀÌ·¯½º
  • halothane hepatitis
    ÇÒ·Îź°£¿°
  • infantile hepatitis
    ¿µ¾Æ°£¿°
  • infectious hepatitis
    Àü¿°¼º°£¿°
  • lupus hepatitis
    ·çǪ½º°£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • non-A, non-B hepatitis
    ABÀ̿ܰ£¿°, ºñA, ºñB°£¿°
  • post-transfusion hepatitis
    ¼öÇ÷Èİ£¿°
  • suppurative hepatitis
    È­³ó°£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • toxipathic hepatitis
    µ¶¹°¼º°£¿°
  • transfusion hepatitis
    (¢¡post-transfusion hepatitis) ¼öÇ÷Èİ£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • hepatitis b
    BÇü°£¿°(¡­ÊÜæú)
  • hepatitis b virus
    BÇü°£¿° ¹ÙÀÌ·¯½º
  • hepatitis contagiosa canis ³ª
    °³Àü¿°¼º°£¿°.
  • hepatitis d
    DÇü°£¿°(¡­ÊÜæú)
  • hepatitis d virus
    DÇü°£¿° ¹ÙÀÌ·¯½º(¡­ÊÜæú¡­)
  • hepatitis e virus
    EÇü°£¿° ¹ÙÀÌ·¯½º(¡­ÊÜæú¡­)
  • hepatitis interstitialis chronica ³ª
    ¸¸¼º °£Áú¼º °£¿°(Ø·àõÊàòõàõÊÜæú).
  • hepatitis,acute viral
    ±Þ¼º¹ÙÀÌ·¯½º¼º
  • hepatitis,alcoholic
    ¾ËÄڿüº
  • hepatitis,carrier state
    º¸±ÕÀÚ(ÜÁжíº)
  • hepatitis,cholangiolitic
    ¼¼´ã°ü¿°¼º
  • hepatitis,cholestatic
    ´ãÁóÁ¤Ã¼¼º
  • hepatitis,delta
    µ¨Å¸
  • hepatitis,fulminant
    Àü°Ý¼º
  • hepatitis,lupoid
    ³¶Ã¢¸ð¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • hepatitis
    °£¿°(ÊÜæú).
  • hepatitis A virus(HAV)
    AÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis A virus (HAV)
    AÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis B core antigen (HBc Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • hepatitis B virus(HBV)
    BÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis C virus(HCV)
    CÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis D coinfection
    D Çü °£¿°µ¿½Ã°¨¿°
  • hepatitis D virus(HDV)
    DÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis E virus(HEV)
    EÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis F virus(HFV)
    FÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis G virus(HGV)
    GÇü °£¿°¹ÙÀÌ·¯½º
  • hepatitis a
    AÇü°£¿°(¡­ÊÜæú)
  • hepatitis a virus
    AÇü°£¿° ¹ÙÀÌ·¯½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CLH Chronic Lobular Hepatitis
CPH Chronic Persistent Hepatitis
CVH Chronic Viral Hepatitis
CBH chronic benign hepatitis; cutaneous basophilic hypersensitivity
CHB chronic hepatitis B; complete heart block; congenital heart block
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HAART Highly Active Anti-Retroviral Therapy
HAART Highly Active Antiretroviral Therapies
HAART Highly active antiretroviral treatment
PAR Photosynthetically Active Radiation
SAPL Surface-active phospholipid
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chronic lupus erythematosus
    ¸¸¼º È«¹Ý¼º ·çǪ½º
  • chronic lymphocytosis
    ¸¸¼º ¸²ÇÁ±¸ Áõ°¡Áõ
  • chronic marginal gingivitis
    ¸¸¼º º¯¿¬ Ä¡Àº¿°, ¸¸¼º º¯¿¬¼º Ä¡Àº¿°
  • chronic meningoencephalitis
    ¸¸¼º ¼ö¸· ³ú¿°
  • chronic motor or vocal tic disorder
    ¸¸¼º ¿îµ¿¼º ȤÀº À½¼ºÆ½ Àå¾Ö
  • chronic mucocutaneous candidiasis
    ¸¸¼º Á¡¸· ÇǺΠĵµð´ÙÁõ, ¸¸¼º Á¡¸· Ç¥ÇǼº ĵµð´ÙÁõ, ¸¸¼º Á¡¾× Á¡¸· Ä­µð´ÙÁõ
    1. Ä­µð´Ù¿¡ ÀÇÇØ »ý±â´Â Ç¥À缺 Áø±ÕÁõÀ¸·Î ÇǺΠ¶Ç´Â Á¡¸·À» ħÅõÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ªºÎÀüÀ» ¹è°æÀ¸·Î À¯¼Ò¾Æ±â¿¡ ¹ß»ýÇÏ´Â ÇǺÎÁ¡¸· ö °áÇ̼º ºóÇ÷, ºñŸ¹Î A °áÇÌÁõ ÇÕº´ÀÌ º¸À̰í À¯Àü Çü½Ä µî¿¡ µû¶ó ¸î °¡Áö·Î ºÐ·ùµÇ°í ÀÖ´Ù. 2. ´Ù¾çÇÑ ÇüÅÂÀÇ ³»ÀçµÈ ¸é¿ª ÀÌ»óÀ» °¡Áø ȯÀÚ´Â ¶§¶§·Î ÇǺÎ, ¼ÕÅé, ±×¸®°í ±¸°­ Á¡¸·¿¡ ±¤¹üÀ§ÇÑ Äµµð´ÙÀÇ ±ºÁýÀ» º¸¿©ÁØ´Ù. ±×¸®°í ÃþÀ» ÀÌ·é µÎ²¨¿î À§¸·ÀÌ Çü¼ºµÈ´Ù.
  • chronic muscle tension
    ¸¸¼º ±ÙÀ° ±äÀå
  • chronic myelitis
    ¸¸¼º ô¼ö¿°
  • chronic myelogenous leukemia
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Àå³âÃþ¿¡ ÁÖ·Î ¹ß»ýÇÏ¸ç ¹éÇ÷º´ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÑ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Á¶Ç÷¸ð¼¼Æ÷ ¼öÁØÀÇ ¾Ï¼º Áõ½ÄÀ¸·Î Áø¼º ÀûÇ÷±¸ Áõ°¡Áõ, Ç÷¼ÒÆÇ Áõ°¡Áõ ¹× °ñ¼ö ¼¶À¯È­Áõ°ú ÇÔ²² °ñ¼ö Áõ½Ä¼º ÁúȯÀ¸·Î ºÐ·ùµÈ´Ù. ¿°»öü 9¹ø°ú 22¹øÀÇ »óÈ£ ÀüÀ§·Î ÀÎÇÑ Çʶóµ¨ÇÇ¾Æ ¿°»öü¿Í ±× »ê¹°ÀÎ bcr-ablÀÌ 95% À̻󿡼­ ¾ç¼ºÀ¸·Î ÀÌ ÁúȯÀÇ º´Àΰú °ü°è°¡ ÀÖ´Â °ÍÀ¸·Î ÀÌÇØµÇ°í ÀÖ´Ù. ÁÖ Áõ»óÀº ºñÀå ºñ´ë·Î ÀÎÇÑ º¹ºÎ ÆØ¸¸ÀÌ Æ¯Â¡ÀûÀÌ¸ç ±×¿Ü °ú´ë»çÁõ µî ÀϹÝÀûÀÎ ¹éÇ÷º´ÀÇ Áõ»óÀÌ ÀÖ´Ù. Áø´ÜÀº Ç÷¾× ¼Ò°ß°ú °ñ¼ö ¼Ò°ß ±×¸®°í ¿°»öü ¹× ºÐÀÚ»ý¹°ÇÐ °Ë»ç¿¡ ÀÇÇÑ bcr-abl ÀÇ Áõ¸í¿¡ ÀÇÇÑ´Ù. ÀÌ ÁúȯÀÇ °æ°ú´Â ¾à 3³âÀÇ ¸¸¼º±â¸¦ Áö³ª°í Àüȯ±â¸¦ °Åó ±Þ¼º ¹éÇ÷º´À¸·Î ÀüȯµÇ¸ç À̶§´Â ÇöÀç ¾Ë·ÁÁø ¾î¶°ÇÑ Ä¡·á ¹æ¹ý¿¡µµ Àß ¹ÝÀÀÇÏÁö ¾Ê´Â´Ù. Ä¡·á´Â °ú°Å¿¡´Â busulfan À̶ó´Â Ç×¾ÏÁ¦°¡, ±Ù·¡¿¡´Â hydrea°¡ ÁÖ·Î »ç¿ëµÇ°í ÀÖÀ¸³ª À̵éÀº ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö ¸øÇÏ¸ç ¹éÇ÷±¸ÀÇ Á¶Àý¿¡¸¸ µµ¿òÀÌ µÉ »Ó Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ÀÖ´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇÏÁö´Â ¸øÇÑ´Ù. ±Ù·¡¿¡´Â homoharringtonine µîÀÇ ¾àÁ¦°¡ ¿¬±¸µÇ°í ÀÖ´Ù. 1990³â´ë ¿¡ µîÀåÇÑ ¾ËÆÄÀÎÅÍÆä·Ð ¿ä¹ýÀº ¾à 80%¿¡¼­ Ç÷¾× ¼Ò°ßÀÌ Á¤»óÈ­µÇ°í 20-30%¿¡¼­ Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ¼Ò½ÇµÇ´Â µî ¿ì¼öÇÑ ¼ºÀûÀ» º¸À̰í ÀÖÀ¸³ª ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö´Â ¸øÇÏ¸ç ¸¸¼º±â¸¦ ¾à 5³â Á¤µµ·Î ¿¬Àå½ÃŲ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´À» ¿ÏÄ¡½Ãų ¼ö ÀÖ´Â À¯ÀÏÇÑ Ä¡·á ¹æ¹ýÀº µ¿Á¾ °ñ¼ö À̽ÄÀ¸·Î 55¼¼±îÁö ½ÃÇàÀÌ µÈ´Ù. °ñ¼ö ÀÌ½Ä ÈÄ Àå±â ¹«º´ »ýÁ¸À²Àº ¾à 60-70%ÀÌ¸ç Æ¯È÷ Áø´ÜµÈ ÈÄ 1³â À̳»¿¡ ½ÃÇàÇÏ´Â °ÍÀÌ ±Ç°íµÈ´Ù.
  • chronic myelomonocytic leukemia
    ¸¸¼º °ñ¼ö¼º ´Ü±¸ ¹éÇ÷º´
  • chronic myocarditis
    ¸¸¼º ½É±Ù¿°
  • chronic nociceptive input
    ¸¸¼º Ä§ÇØ¼ö¿ë¼º ÀÔ·Â, ¸¸¼º À¯Çؼö¿ë¼º ÀÔ·Â
  • chronic nonspecific dermatitis
    ¸¸¼º ºñƯÀ̼º ÇǺο°
  • chronic organic brain syndrome
    ¸¸¼º ±âÁú¼º ³ú ÁõÈıº
  • chronic osteomyelitis
    ¸¸¼º °ñ¼ö¿°
    ¾àÇÑ Àڱؿ¡ ÀÇÇØ »ý±â¸ç ÁÖº¯¿¡ °ñ Çü¼ºÀ» µ¿¹ÝÇÑ °ñ¸·ÀÇ ±¹¼ÒÀû Áõ»óÀÌ´Ù. °ÅÀÇ ÀþÀº »ç¶÷¿¡¼­ ¹ß»ýÇϸç, È£¹ßºÎ´Â °æ°ñÀÇ Àü¸é°ú ÇϾÇÀÌ´Ù. Ä¡Åë°ú »óÇϾÇÀÇ ÅëÁõÀÌ ³ªÅ¸³­´Ù. ¶§·Î »óÃþÀÇ ¿¬Á¶Á÷ÀÇ °¨¿°À̳ª ºÀ¿ÍÁ÷¿°ÀÇ °á°ú·Î »ý±ä´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
virus A hepatitis A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
virus B hepatitis A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients.
Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis.
(05 Mar 2000)
virus C hepatitis Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family.
Synonym: hepatitis C, virus C hepatitis.
(05 Mar 2000)
virus hepatitis Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver.
(12 Dec 1998)
virus hepatitis of ducks A disease of very young ducklings, caused by the duck hepatitis virus (family Hepadnoviridae) and manifested as an acute illness of several days followed by death; the principal lesions are an enlarged necrotic liver filled with ecchymotic haemorrhages.
(05 Mar 2000)
peliosis hepatitis A rare condition in which the liver contains very numerous small blood-filled spaces, sometimes lined with endothelium; it may be found incidentally or rupture may cause intraperitoneal haemorrhage.
(05 Mar 2000)
goose viral hepatitis An acute, highly fatal disease of goslings and Muscovy ducklings caused by the goose parvovirus and characterised by anorexia, feather loss, and tissue haemorrhages.
Synonym: Derzsy's disease.
(05 Mar 2000)
cholangiolitic hepatitis Hepatitis with inflammatory changes around small bile ducts, producing mainly obstructive jaundice; may be due to viral infection or bacterial infection ascending biliary tree because of obstruction.
(05 Mar 2000)
cholestatic hepatitis Jaundice with bile stasis in inflamed intrahepatic bile ducts; usually due to toxic effects of a drug.
(05 Mar 2000)
mouse hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
mouse hepatitis virus A coronavirus, in the family Coronaviridae, that in the presence of Eperythrozoon coccoides causes fatal hepatitis in newly weaned mice; otherwise causes inapparent infection.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
MS-1 hepatitis A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
murine hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
halothane hepatitis Hepatocellular damage said to result from the administration of halothane anaesthesia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á